Cancers, Vol. 12, Pages 727: The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NCLC) Cells
Cancers, Vol. 12, Pages 727: The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NCLC) Cells
Cancers doi: 10.3390/cancers12030727
Authors:
Dong Young Kang
Nipin Sp
Eun Seong Jo
Alexis Rugamba
Dae Young Hong
Hong Ghi Lee
Ji-Seung Yoo
Qing Liu
Kyoung-Jin Jang
Young Mok Yang
Non-small-cell lung cancer (NSCLC) is the most common lung cancer subtype and accounts for more than 80% of all lung cancer cases. Epidermal growth factor receptor (EGFR) phosphorylation by binding growth factors such as EGF activates downstream prooncogenic signaling pathways including KRAS-ERK, JAK-STAT, and PI3K-AKT. These pathways promote the tumor progression of NSCLC by inducing uncontrolled cell cycle, proliferation, migration, and programmed death-ligand 1 (PD-L1) expression. New cytotoxic drugs have facilitated considerable progress in NSCLC treatment, but side effects are still a significant cause of mortality. Gallic acid (3,4,5-trihydroxybenzoic acid; GA) is a phenolic natural compound, isolated from plant derivatives, that has been reported to show anticancer effects. We demonstrated the tumor-suppressive effect of GA, which induced the decrease of PD-L1 expression through binding to EGFR in NSCLC. This binding inhibited the phosphorylation of EGFR, subsequently inducing the inhibition of PI3K and AKT phosphorylation, which triggered the activation of p53. The p53-dependent upregulation of miR-34a induced P...
Source: Cancers - Category: Cancer & Oncology Authors: Dong Young Kang Nipin Sp Eun Seong Jo Alexis Rugamba Dae Young Hong Hong Ghi Lee Ji-Seung Yoo Qing Liu Kyoung-Jin Jang Young Mok Yang Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer